The estimated Net Worth of Martin J Colombatto is at least $9.11 millier dollars as of 19 November 2020. Martin Colombatto owns over 8,700 units of Catheter Precision stock worth over $9,109 and over the last 6 years Martin sold RMED stock worth over $0.
Martin has made over 1 trades of the Catheter Precision stock since 2020, according to the Form 4 filled with the SEC. Most recently Martin bought 8,700 units of RMED stock worth $50,286 on 19 November 2020.
The largest trade Martin's ever made was buying 8,700 units of Catheter Precision stock on 19 November 2020 worth over $50,286. On average, Martin trades about 1,243 units every 0 days since 2018. As of 19 November 2020 Martin still owns at least 15,439 units of Catheter Precision stock.
You can see the complete history of Martin Colombatto stock trades at the bottom of the page.
Martin's mailing address filed with the SEC is C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD, CA, 92011.
Over the last 6 years, insiders at Catheter Precision have traded over $709,539 worth of Catheter Precision stock and bought 199,373 units worth $197,741 . The most active insiders traders include Jeffrey J Kraws, Jonathan Will Mc Guire et Dean Burstein Melissa Dean .... On average, Catheter Precision executives and independent directors trade stock every 34 days with the average trade being worth of $12,983. The most recent stock trade was executed by Andrew C. Jackson on 20 November 2021, trading 2,684 units of RMED stock currently worth $7,032.
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
Catheter Precision executives and other stock owners filed with the SEC include: